<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://dirros.openscience.si/IzpisGradiva.php?id=22721"><dc:title>Hereditary α-tryptasemia is associated with anaphylaxis to antibiotics and monoclonal antibodies</dc:title><dc:creator>Korošec,	Peter	(Avtor)
	</dc:creator><dc:creator>Lyons,	Jonathan J.	(Avtor)
	</dc:creator><dc:creator>Svetina,	Manca	(Avtor)
	</dc:creator><dc:creator>Koudová,	Monika	(Avtor)
	</dc:creator><dc:creator>Bittóová,	Martina	(Avtor)
	</dc:creator><dc:creator>Zidarn,	Mihaela	(Avtor)
	</dc:creator><dc:creator>Sedláčková,	Lenka	(Avtor)
	</dc:creator><dc:creator>Rijavec,	Matija	(Avtor)
	</dc:creator><dc:creator>Kopač,	Peter	(Avtor)
	</dc:creator><dc:subject>immunology</dc:subject><dc:subject>drug allergy</dc:subject><dc:subject>anaphylaxis</dc:subject><dc:subject>antibiotics</dc:subject><dc:subject>monoclonal antibodies</dc:subject><dc:subject>α-tryptase</dc:subject><dc:subject>hereditary α-tryptasemia</dc:subject><dc:description>Background
Hereditary α-tryptasemia, a genetic trait caused by increased α-tryptase copy number, is associated with idiopathic and venom anaphylaxis.
Objective
We aimed to determine the impact of tryptase genotypes on drug-induced anaphylaxis.
Methods
A prospective discovery cohort of 99 patients from a referral center in Slovenia with acute anaphylaxis to drugs underwent tryptase genotyping by droplet digital PCR. For validation, we included a cohort of 26 patients from the Czech Republic. Associated inciting agents and the severity of the reactions were subsequently examined.

Results
Hereditary α-tryptasemia was associated with drug-induced anaphylaxis with a prevalence of 13% (n = 13 of 99) in the discovery cohort and 15% in the validation cohort (n = 4 of 26). Hereditary α-tryptasemia was identified in every individual with elevated basal serum tryptase levels (11.6-21.9 ng/mL; n = 14) within both cohorts of patients. Hereditary α-tryptasemia was more prevalent in individuals with antibiotic- or mAb-induced anaphylaxis in both the discovery and validation cohorts (n = 13 of 51; 26%) compared to those with anaphylaxis resulting from neuromuscular blocking agents, nonsteroidal anti-inflammatory drugs, contrast, chlorhexidine, or other drugs (n = 5 of 74; 7%; P = .02; odds ratio = 4.1; 95% CI, 1.3-11.1). Overall, we found fewer individuals with no ⍺-tryptase than in the general population, and there was a trend for subjects with more ⍺-tryptase copies to have more severe reactions. Thus, among subjects with three ⍺-tryptase copies, the prevalence of severe anaphylaxis was 73%, compared with 59% with one to two ⍺-tryptase copies and 58% for subjects without ⍺-tryptase.
Conclusions
Risk for anaphylaxis to antibiotics and biologics is associated with inherited differences in α-tryptase–encoding copies at Tryptase α/β1 .</dc:description><dc:publisher>Elsevier, 2013-</dc:publisher><dc:date>2025</dc:date><dc:date>2025-06-18 14:01:59</dc:date><dc:type>Neznano</dc:type><dc:identifier>22721</dc:identifier><dc:source>The journal of allergy and clinical immunology. In practice</dc:source><dc:language>sl</dc:language><dc:rights>© 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma &amp; Immunology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</dc:rights></rdf:Description></rdf:RDF>
